A comprehensive analysis of female participation in cardiovascular trials involving the WCN investigator network.

ABSTRACT:

Background

Prior studies showed underrepresentation of females in cardiovascular disease (CVD) clinical trials, potentially hindering accurate treatment effect estimates. We assessed the female contribution to treatment effect estimates in selected CVD trials and explored sex differences in efficacy outcomes.

Methods

We analyzed completed (1997-2024) randomized controlled CVD trials performed via the Dutch WCN Investigator Network. Female participation was quantified using the Participation to Prevalence (in the population) Ratio (PPR_F). In trials with a cardiovascular event as the primary efficacy endpoint, a meta-analysis was conducted to evaluate differences in treatment effect on the study-specific primary endpoint between females and males using a random-effe

SUBMITTER: van der Bijl MF 

PROVIDER: S-EPMC12638513 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature